A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma
Myxoid liposarcomas (MPLS) constitute almost 10-20% of all liposarcomas and 5% of all soft tissue sarcomas (STS) [1,2]. Its incidence peaks in the fourth and fifth decade of life with an equal distribution between men and women [1]. At presentation, one third of MPLS patients are metastatic mainly to extrapulmonary sites such as the retroperitoneum, axilla and bones [2,3]. MPLS is characterized by the chromosomal translocation t(12:16) (q13:p11) present in 95% of patients and producing the FUS-CHOP oncoprotein [3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tarek Assi, Joseph Kattan, Elie El Rassy, Charles Honore, Sarah Dumont, Olivier Mir, Axel Le Cesne Tags: Anti-Tumour Treatment Source Type: research
More News: Cancer | Cancer & Oncology | Liposarcoma | Sarcomas | Soft Tissue Sarcoma | Translocation | Women